Aegerion's $47m 10.8% discount offering pulls stock down 11%
This article was originally published in Scrip
Executive Summary
Aegerion Pharmaceuticals' stock price predictably dipped 11% on 14 June when it priced a common stock offering of 3.4 million shares at $14.75 at a 10.8% discount to its market price on 13 June. The company expects to net $47.3 million, using it pursue regulatory approvals and commercialization of lomitapide.